Literature DB >> 15116244

A review of the therapeutic uses of thrombin.

Roger L Lundblad1, Ralph A Bradshaw, Don Gabriel, Thomas L Ortel, Jeffrey Lawson, Kenneth G Mann.   

Abstract

Thrombin is the product of the hemostatic response essential to the conversion of fibrinogen to fibrin. In addition, it is also responsible for the aggregation of blood platelets in the formation of the "platelet plug" as well as the activation of factor VIII, factor V, factor XI, factor XIII and protein C. The action of thrombin is not confined to the hemostatic response as it also has a critical function in the wound healing process by stimulating 'mitogenic' events through interaction with cell surface receptors. In this review, we consider the various biological activities of thrombin as they relate to current therapeutic use. While there has been considerable interest in the development of fibrin sealant products, there has been considerably less interest in documenting the continuing use of thrombin as a therapeutic. The use of thrombin for topical hemostasis and the treatment of pseudoaneurysms will be discussed in detail. It is concluded that the use of thrombin as a drug will not only continue but also will significantly increase. However, the availability of a safe human thrombin preparation will be critical for the continued use of thrombin as a therapeutic.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15116244     DOI: 10.1160/TH03-12-0792

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Delivery of water-soluble drugs using acoustically triggered perfluorocarbon double emulsions.

Authors:  Mario L Fabiilli; James A Lee; Oliver D Kripfgans; Paul L Carson; J Brian Fowlkes
Journal:  Pharm Res       Date:  2010-09-25       Impact factor: 4.200

2.  Infection-induced thrombin production: a potential novel mechanism for preterm premature rupture of membranes (PPROM).

Authors:  Liping Feng; Terrence K Allen; William P Marinello; Amy P Murtha
Journal:  Am J Obstet Gynecol       Date:  2018-04-13       Impact factor: 8.661

3.  Acute in-vivo evaluation of bleeding with Gelfoam plus saline and Gelfoam plus human thrombin using a liver square lesion model in swine.

Authors:  George L Adams; Roberto J Manson; Vic Hasselblad; Linda K Shaw; Jeffrey H Lawson
Journal:  J Thromb Thrombolysis       Date:  2008-07-16       Impact factor: 2.300

Review 4.  Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.

Authors:  DaShawn A Hickman; Christa L Pawlowski; Ujjal D S Sekhon; Joyann Marks; Anirban Sen Gupta
Journal:  Adv Mater       Date:  2017-11-22       Impact factor: 30.849

5.  Thrombin@Fe3O4 nanoparticles for use as a hemostatic agent in internal bleeding.

Authors:  Emiliya M Shabanova; Andrey S Drozdov; Anna F Fakhardo; Ivan P Dudanov; Marina S Kovalchuk; Vladimir V Vinogradov
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

Review 6.  Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective.

Authors:  Fanny Risser; Ivan Urosev; Joanan López-Morales; Yang Sun; Michael A Nash
Journal:  Biophys Rev       Date:  2022-04-06

7.  Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding.

Authors:  Steven D Hughes; Paul D Bishop; Richard Garcia; Tracy Zhang; W Allan Alexander
Journal:  Ann Surg Innov Res       Date:  2009-11-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.